Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

NCT ID: NCT06872684

Last Updated: 2026-01-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 183 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-20
• Study Completion Date: 2031-01-31

Brief Summary

The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.

Detailed Description

The Surpass Elite with Guardian Flow Diverter System is indicated for use in the endovascular treatment of adults (age 18 or above) with unruptured wide-neck saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 3.0 millimeters (mm) and ≤ 6.0 mm and located on the ICA or its branches.

Conditions

Aneurysm; Aneurysm, Intracranial

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Surpass Elite with Guardian Flow Diverter

This is a prospective single arm study in which all subjects who present for Surpass Elite with Guardian flow diverter implantation, provide informed consent, and meet inclusion/exclusion criteria may receive treatment.

Group Type: EXPERIMENTAL

Surpass Elite with Guardian Flow Diverter System

Intervention Type: DEVICE

The Surpass Elite with Guardian Flow Diverter System is indicated for use in the endovascular treatment of adults (age 18 or above) with unruptured wide-neck saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 3.0 millimeter (mm) and ≤ 6.0 mm and located on the Internal Carotid Artery (ICA) or its branches.

Interventions

Surpass Elite with Guardian Flow Diverter System

The Surpass Elite with Guardian Flow Diverter System is indicated for use in the endovascular treatment of adults (age 18 or above) with unruptured wide-neck saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 3.0 millimeter (mm) and ≤ 6.0 mm and located on the Internal Carotid Artery (ICA) or its branches.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age is ≥18 and ≤80 years at the time of consent

2. Has a single unruptured target intracranial aneurysm (IA) of any size with the following characteristics:

1. Is located on the internal carotid artery or its branches

2. Has a wide neck (wide neck typically defined as neck width ≥ 4 millimeter (mm), or dome to neck ratio ≤ 2.0) or no discernible neck

3. Aneurysm is either saccular or fusiform in nature

3. Has a parent vessel diameter ≥ 3.0 mm to ≤ 6.0 mm at the largest diameter

4. There is documented risk-benefit of endovascular treatment that outweighs the risks of intracranial aneurysm rupture during the subject's expected lifetime if left untreated.

Exclusion Criteria

1. Has an extradural target aneurysm

2. Has a target aneurysm in the posterior circulation

3. Perforator or branch vessel, inclusive of the posterior communicating artery, arises from the target aneurysm body or neck (branches or arteries must arise or connect from the parent vessel separate from the aneurysm or neck to not be excluded from trial)

4. Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at a point of vessel bifurcation

5. Has vessel characteristics, such as severe tortuosity (cavernous Internal Carotid Artery (cICA) Type IV1), stenosis (>70%), or morphology that would preclude safe endovascular access or proper deployment of the trial device to the target aneurysm

6. Received previous treatment for the target aneurysm or parent artery where it would interfere with the placement or proper apposition of the device

7. Has a medical contraindication to trial or procedure related antiplatelet medications (aspirin, clopidogrel/Plavix, ticagrelor, and heparin), local or general anesthesia, or life-threatening allergy to contrast dye

8. Has a known severe allergy to nickel, chromium cobalt, tungsten, or platinum

9. Patients with heparin hypersensitivity, including patients with a previous incident of Heparin-Induced Thrombocytopenia (HIT).

10. Modified Rankin Score (mRS) assessment is ≥ 3 at pre-procedure exam

11. Presence of unstable neurological deficit (i.e., worsening of clinical condition in the last 30 days prior to the index procedure)

12. Subarachnoid hemorrhage occurred within 30 days prior to the index procedure

13. Major surgery (including previous intracranial implant) either occurred within 30 days prior to the index procedure date or is planned to occur within 120 days following the index procedure date

14. Has more than one intracranial aneurysm (IA) that requires treatment within 12 months after the index procedure

15. Received previous intracranial implant associated with the symptomatic or vascular distribution within the past 84 days prior to treatment date

16. Chronic anticoagulation therapy is ongoing or known coagulopathy exists

17. Has atrial fibrillation with or without pacemaker.

18. Has other known serious concurrent medical conditions such as cardiovascular disease (including recent myocardial infarction [<12 weeks], symptomatic congestive heart failure, or carotid stenosis), kidney failure (>2.0 mg/dl serum creatinine), pulmonary disease, uncontrolled diabetes, progressive neurologic disorders, terminal cancer, vasculitis, high risk of ischemic stroke or recent stroke

19. Has acute life-threatening illness (e.g., acute kidney or heart failure) other than the neurological disease to be treated in this trial

20. Evidence of active infection at the time of treatment

21. Life expectancy is less than 5 years due to other illness or condition (in addition to an intracranial aneurysm)

22. Unable to comply with the trial follow up requirements due to conditions such as dementia or psychiatric problems, active substance abuse, or history of non-compliance with medical advice, as determined by the investigator

23. Pregnant or breast- feeding women or women who wish to become pregnant during the length of trial participation

24. Presence of intracranial mass (tumor, except meningioma, abscess, or other infection), non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm

25. Enrollment in another study involving an investigational product that could confound the outcomes of this trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stryker Neurovascular

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexander Coon, MD

Role: PRINCIPAL_INVESTIGATOR

Carondelet at St. Joesphs

David Fiorella, MD

Role: PRINCIPAL_INVESTIGATOR

Stony Brook University

Locations

Carondelet St. Joseph's Hospital

Tucson, Arizona, United States

Site Status: RECRUITING

University of California Davis Health

Davis, California, United States

Site Status: RECRUITING

Lahey Hospital and Medical Center

Burlington, Massachusetts, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Uloma Isang

Role: CONTACT

uloma.isang@stryker.com

619-817-1427

Darren LaCour, Jr.

Role: CONTACT

darren.lacour@stryker.com

949-288-1547

Facility Contacts

Rachael Taoka

Role: primary

Rachael2.taoka@tenethealth.com

520-873-1592

Savina Nguyen

Role: primary

savnguyen@ucdavis.edu

916-551-3234

Sandy Alvarez

Role: primary

Sandy.L.Alvarez@lahey.org

786-580-0186

Other Identifiers

CDM10001836

Identifier Type: -

Identifier Source: org_study_id